Novartis AG Registered Shares NVSEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVSEF is a good fit for your portfolio.
News
-
Trending: Novartis Raises Profit Guidance as It Prepares for Patent Expirations
-
Novartis lifts guidance again as demand climbs for top drugs
-
Novartis Raises Profit Guidance as Key Drugs Boost Sales — Update
-
Novartis Raises Profit Guidance as Key Drugs Boost Sales
-
Novartis On Pace for Record High Close — Data Talk
-
Novartis on Track for Record High Close — Data Talk
-
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement
-
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout
Trading Information
- Previous Close Price
- $109.90
- Day Range
- $104.70–109.00
- 52-Week Range
- $90.24–110.00
- Bid/Ask
- $103.06 / $115.31
- Market Cap
- $216.58 Bil
- Volume/Avg
- 422 / 25,850
Key Statistics
- Price/Earnings (Normalized)
- 15.19
- Price/Sales
- 4.52
- Dividend Yield (Trailing)
- 3.52%
- Dividend Yield (Forward)
- 3.52%
- Total Yield
- 6.01%
Company Profile
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 76,057
- Website
- https://www.novartis.com
Competitors
Valuation
|
Metric
|
NVSEF
|
JNJ
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.19 | 15.33 | 9.84 |
Price/Book Value | 5.19 | 5.40 | 4.65 |
Price/Sales | 4.52 | 4.56 | 2.12 |
Price/Cash Flow | 13.84 | 17.34 | 9.62 |
Price/Earnings
NVSEF
JNJ
GSK
Financial Strength
|
Metric
|
NVSEF
|
JNJ
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.61 | 0.77 | 0.57 |
Current Ratio | 0.93 | 1.07 | 0.87 |
Interest Coverage | 12.34 | 24.45 | 8.94 |
Quick Ratio
NVSEF
JNJ
GSK
Profitability
|
Metric
|
NVSEF
|
JNJ
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.97% | 13.17% | 11.25% |
Return on Equity (Normalized) | 33.01% | 32.42% | 51.21% |
Return on Invested Capital (Normalized) | 20.66% | 20.93% | 22.40% |
Return on Assets
NVSEF
JNJ
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Qpgqblzqh | Ylfss | $724.5 Bil | |||
| Johnson & Johnson
JNJ
| Txclcyb | Hwndt | $386.7 Bil | |||
| AbbVie Inc
ABBV
| Pzmybrv | Ptyqs | $327.0 Bil | |||
| Merck & Co Inc
MRK
| Zwqtrfjx | Bpr | $317.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Qcphmvqg | Whqzd | $261.9 Bil | |||
| AstraZeneca PLC ADR
AZN
| Fptprkfmy | Xklj | $242.7 Bil | |||
| Novartis AG ADR
NVS
| Fdrjhrk | Wvzr | $224.0 Bil | |||
| Amgen Inc
AMGN
| Dlbfsrbqs | Hkynw | $179.6 Bil | |||
| Pfizer Inc
PFE
| Vwrjqss | Dxcts | $174.4 Bil | |||
| Sanofi SA ADR
SNY
| Lwkdzztsc | Jcqtk | $131.7 Bil |